Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molibresib (Primary)
  • Indications Acute myeloid leukaemia; Burkitt's lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 09 Nov 2022 Results published in the Clinical Cancer Research
    • 13 May 2020 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2020 Planned End Date changed from 16 Oct 2023 to 30 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top